Subcutaneous immunoglobulin as first‐line therapy in treatment‐naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study

Abstract

In treatment-naive patients with CIDP, short-lasting SCIG and IVIG therapy improve motor performance to a similar degree, but with earlier maximal improvement following IVIG than SCIG treatment.

Clinical‐neurophysiological correlations in chronic inflammatory demyelinating polyradiculoneuropathy patients treated with subcutaneous immunoglobulin

“…CIDP patients were clinically evaluated using established assessment scales and scores at baseline (before SCIg treatment) and after 24 and 48 months of SCIg treatment. Strength was evaluated using the modified Medical Research Council sum (MRCS) score, a summation of the MRC grades (0‐5) of the following muscle pairs: shoulder abductors, elbow flexors, wrist extensors, knee extensors, and ankle dorsiflexors . The MRCS score, therefore, ranged from 0 (complete paralysis) to 60 (normal strength).…”

Relative leucopenia and hemolytic anemia following infusion of immunoglobulin

“…Previously, we have evaluated WBC counts and hemoglobin levels in a cohort of treatment-naive patients with chronic inflammatory demyelinating polyneuropathy (CIDP) receiving IVIG or subcutaneous immunoglobulin (SCIG) as described elsewhere [2]. Studies were performed at baseline, 2, 5 and 10 weeks after initiation of therapy.…”

“…Our study included 19 patients, whereas 57 patients participated in the study of Totzeck et al, leading to better statistical power. Furthermore, the patients were studied after 6 days [1] and 12 days [2], the former being optimal.…”

Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies

“…There is little known about SCIg in patients who are treatment‐naive or who have not reached a stable state on IVIg treatment. In a recent short‐lasting study by Markvardsen et al . for treatment‐naive CIDP patients, both IVIg and SCIg therapies improved motor performance to a similar degree, but with earlier maximal improvement with IVIg.…”